─New Findings Demonstrate CM-101's
Anti-Inflammatory and Anti-Fibrotic Effects Are Highly Relevant to
Inflammatory Lung Diseases─
TEL
AVIV, Israel, Nov. 9, 2022
/PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB)
(Chemomab), a clinical-stage biotechnology company focused on the
discovery and development of innovative therapeutics for fibrotic
and inflammatory diseases with high unmet need, announced that
clinical data presented today showed that CM-101 was safe and
well-tolerated and achieved reductions in biomarkers associated
with lung inflammation and fibrogenesis in a clinical study in
patients hospitalized with COVID-19-derived lung injury. CM-101 is
a first-in-class monoclonal antibody that neutralizes CCL24, a
soluble protein with pro-fibrotic and pro-inflammatory effects. It
is in development for the treatment of fibro-inflammatory
disorders, including primary sclerosingcholangitis (PSC) and
systemic sclerosis (SSc).

The presentation, Treatment with CM-101 Reduced Inflammatory
& Fibrotic Biomarkers in Patients with COVID-19-Derived Lung
Damage, was discussed by Chemomab co-founder and Chief
Scientific Officer Dr. Adi Mor at
the Union World Conference on Lung Health 2022.
Some of the mechanisms underlying lung inflammation resulting
from COVID-19 infection are similar to those seen in chronic
diseases involving lung inflammation and fibrosis, and this study
was initiated by a physician/researcher who treats patients with
systemic sclerosis and other rheumatological diseases. The
objective of the study was to evaluate the drug's safety and
activity in hospitalized COVID-19 patients with severe pneumonia,
including its impact on biomarkers related to lung inflammation
that are also relevant in systemic sclerosis.
The open label, single arm trial enrolled 16 adult COVID-19
patients with severe respiratory involvement. All patients
were hospitalized and were receiving standard of care therapy. All
were treated with a single 10mg/kg intravenous dose of CM-101 on
the first day of the study and followed for 30 days. Clinical
parameters were tested daily during hospitalization and serum
biomarkers were tested at baseline and on days 1, 3, 7 and 30
following drug administration.
Administration of CM-101 to this acutely ill patient population
was found to be safe and well tolerated. CM-101 exposures and
target engagement profiles were similar to what Chemomab
researchers have seen in previous clinical studies of CM-101.
Importantly, rapid reductions in serum biomarkers of lung
inflammation, fibrogenesis and neutrophil activity were observed
post-treatment with CM-101, consistent with the effects seen in
previous preclinical and early clinical data.
Reductions in the serum levels of biomarkers seen in the study
included the cytokines CXCL9 and CXCL10, two biomarkers that are
highly associated with lung inflammation and are known to be
strongly correlated with respiratory severity. For example, CXCL10
was reduced by a median change of 65% from baseline as soon as
24-hours post treatment with CM-101 and further reduced by almost
80% at day 3. The effect was sustained through the end of the
follow-up period.
It was noteworthy too that patients receiving CM-101
demonstrated a rapid and robust median reduction of 50% in
c-reactive protein, or CRP, a well-known general marker of
inflammation, as soon as 48 hours post-administration. CRP
levels were further decreased by more than 90% at day 6 after
CM-101 administration and remained stable until the end of the
follow-up period. CM-101 also demonstrated larger and more rapid
CRP reductions compared to a retrospective Covid-19 control group
who had similar clinical characteristics and also received standard
of care therapy.
Lastly, treatment with CM-101 impacted biomarkers that are
associated with the formation and degradation of the extracellular
matrix, such as Procollagen 4 and C3M, which were highly elevated
in these patients at baseline and were significantly reduced by a
median change of 25% as soon as 72 hours post-treatment, a
reduction that remained stable until the end of the follow-up
period.
"This study confirms and extends the safety and tolerability
profile of CM-101 and demonstrates clinically relevant changes in
biomarkers associated with lung inflammation and fibrogenesis,"
said Dr. Mor. "Moreover, we believe that these results add to the
data suggesting that CM-101 has the potential to attenuate lung
inflammation and fibrosis, further strengthening the rationale for
treating systemic sclerosis patients with this drug. These new
clinical data also contribute to a growing body of evidence
demonstrating CM-101's anti-fibrotic and anti-inflammatory effects
in varied organs including the lung, liver and skin."
More information on the Union World Conference on Lung Health
2022 can be found at https://conf2022.theunion.org/
About Chemomab Therapeutics
Ltd.
Chemomab is a clinical stage biotechnology company focusing on
the discovery and development of innovative therapeutics for
fibrotic and inflammatory diseases with high unmet need. Based on
the unique and pivotal role of the soluble protein CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to bind and block CCL24 activity.
CM-101 has demonstrated the potential to treat multiple severe and
life-threatening fibrotic and inflammatory diseases. It is
currently in Phase 2 trials for primary sclerosing cholangitis and
liver fibrosis, with a Phase 2 trial in systemic sclerosis expected
to open around year-end, with first patients enrolled in early
2023. For more information on Chemomab,
visit chemomab.com.
Forward Looking
Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act. These
forward-looking statements include, among other things, statements
regarding the clinical development pathway for CM-101; the future
operations of Chemomab and its ability to successfully initiate and
complete clinical trials and achieve regulatory milestones; the
nature, strategy and focus of Chemomab; the development and
commercial potential and potential benefits of any product
candidates of Chemomab; and that the product candidates have the
potential to address high unmet needs of patients with serious
fibrosis-related diseases and conditions. Any statements contained
in this communication that are not statements of historical fact
may be deemed to be forward-looking statements. These
forward-looking statements are based upon Chemomab's current
expectations. Forward-looking statements involve risks and
uncertainties. Because such statements deal with future events and
are based on Chemomab's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of Chemomab could differ materially from those
described in or implied by the statements in this presentation,
including: the uncertain and time-consuming regulatory approval
process; risks related to Chemomab's ability to correctly manage
its operating expenses and its expenses; Chemomab's plans to
develop and commercialize its product candidates, focusing on
CM-101; the timing of initiation of Chemomab's planned clinical
trials; the timing of the availability of data from Chemomab's
clinical trials; the timing of any planned investigational new drug
application or new drug application; Chemomab's plans to research,
develop and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of Chemomab's product candidates; Chemomab's
commercialization, marketing and manufacturing capabilities and
strategy; Chemomab's ability to protect its intellectual property
position; and the requirement for additional capital to continue to
advance these product candidates, which may not be available on
favorable terms or at all. Additional risks and uncertainties
relating to Chemomab's and its business can be found under the
caption "Risk Factors" and elsewhere in Chemomab's filings and
reports with the SEC. Chemomab expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Chemomab's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Contacts:
Media:
Barbara
Lindheim
BLL Partners for Chemomab
Phone: +1-917-355-9234
barbara@chemomab.com
Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1-917-734-7387
ir@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-presents-clinical-data-from-investigator-initiated-study-showing-cm-101-reduced-inflammatory-and-fibrogenesis-related-biomarkers-in-patients-with-severe-lung-injury-derived-from-covid-19-301672588.html
SOURCE Chemomab Therapeutics, Ltd.